Comparative Pharmacology
Head-to-head clinical analysis: BAL versus CUPRIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAL versus CUPRIMINE.
BAL vs CUPRIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
Clinical Note
moderateBalsalazide + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Acetyldigitoxin
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Ouabain
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
Renal: ~80% as unchanged drug, biliary/fecal: <5%
Category C
Category C
Chelating Agent
Chelating Agent
"The serum concentration of Ouabain can be decreased when it is combined with Balsalazide."